

Ganesh V Raj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/47299/publications.pdf>

Version: 2024-02-01

111
papers

8,036
citations

93792

39
h-index

56606

87
g-index

114
all docs

114
docs citations

114
times ranked

11498
citing authors

#	ARTICLE	IF	CITATIONS
1	Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity. PLoS ONE, 2022, 17, e0258876.	1.1	7
2	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Frontiers in Oncology, 2022, 12, 779182.	1.3	0
3	The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. Clinical and Translational Medicine, 2022, 12, e695.	1.7	8
4	Targeting radioresistance and replication fork stability in prostate cancer. JCI Insight, 2022, 7, .	2.3	4
5	Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nature Cancer, 2022, 3, 866-884.	5.7	8
6	A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells. Oncogene, 2021, 40, 1106-1117.	2.6	24
7	Dynamic differences between DNA damage repair responses in primary tumors and cell lines. Translational Oncology, 2021, 14, 100898.	1.7	6
8	Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. Endocrine-Related Cancer, 2021, 28, R31-R46.	1.6	3
9	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear Medicine and Biology, 2021, 93, 37-45.	0.3	2
10	Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, e129-e134.	0.9	1
11	LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. Communications Biology, 2021, 4, 1235.	2.0	11
12	Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 13085.	1.8	10
13	RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell Chemical Biology, 2020, 27, 105-121.e14.	2.5	38
14	Jean Wilson and His Legacy, 50 Years and Counting. Urology, 2020, 153, 1-5.	0.5	0
15	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications, 2020, 11, 5488.	5.8	25
16	Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer. Cancer Letters, 2020, 488, 40-49.	3.2	11
17	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
18	The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. Journal of Clinical Investigation, 2020, 130, 3987-4005.	3.9	37

#	ARTICLE	IF	CITATIONS
19	SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
20	IFN β -Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing. <i>Cancer Research</i> , 2019, 79, 1098-1112.	0.4	63
21	A Structure-Activity Relationship Study of Bis-Benzamides as Inhibitors of Androgen Receptor-Coactivator Interaction. <i>Molecules</i> , 2019, 24, 2783.	1.7	6
22	Biomarkers for platinum sensitivity in bladder cancer: are we there yet?. <i>Translational Andrology and Urology</i> , 2019, 8, S236-S239.	0.6	4
23	Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth. <i>Molecular Cancer</i> , 2019, 18, 113.	7.9	10
24	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
25	An evaluation of fulvestrant for the treatment of metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1819-1829.	0.9	18
26	Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase. <i>Oncogene</i> , 2019, 38, 5580-5598.	2.6	33
27	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1341-1354.	1.9	41
28	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404.	2.6	42
29	Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 150.	2.2	14
30	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	0.8	24
31	Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 249-259.	1.9	6
32	Molecular mechanisms of enzalutamide resistance in prostate cancer. , 2019, 2, 189-197.		2
33	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 651-651.	0.8	0
34	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16100-e16100.	0.8	0
35	Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. <i>BJU International</i> , 2018, 121, 9-21.	1.3	60
36	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 796-808.	2.9	103

#	ARTICLE	IF	CITATIONS
37	A new class of agents for estrogen-receptor-positive breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 325-328.	1.3	2
38	Electrical Impedance Measurements of Biological Cells in Response to External Stimuli. <i>Analytical Chemistry</i> , 2018, 90, 4320-4327.	3.2	36
39	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	0.5	15
40	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	0.8	21
41	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
42	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	3.2	111
43	Natural history of "second" biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	1.3	12
44	A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. <i>Cell Reports</i> , 2018, 25, 3530-3542.e5.	2.9	204
45	Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 86-96.	3.2	1
46	Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis. <i>Molecular Cancer Research</i> , 2018, 16, 1761-1772.	1.5	15
47	A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	2.1	94
48	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	12.5	142
49	Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 825-832.	0.9	34
50	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2017, 198, 1021-1026.	0.2	2
51	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3417-3430.	0.4	79
52	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3101-3112.	0.4	68
53	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.4	20
54	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , 2017, 77, 4745-4754.	0.4	56

#	ARTICLE	IF	CITATIONS
55	Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. <i>Journal of Hematology and Oncology</i> , 2017, 10, 89.	6.9	60
56	Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer. <i>Diagnostics</i> , 2017, 7, 48.	1.3	23
57	Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers. <i>ELife</i> , 2017, 6, .	2.8	38
58	Abstract 4148: Novel ERX-11 and CDK4/6 inhibitor combination therapy for treating therapy resistant breast cancer. , 2017, , .		1
59	Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. <i>Nature Communications</i> , 2016, 7, 13668.	5.8	134
60	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. <i>Science Advances</i> , 2016, 2, e1501924.	4.7	100
61	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15Åyear experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43.	0.6	24
62	Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. <i>Molecular Cell</i> , 2016, 63, 976-989.	4.5	80
63	The surgeonâ€™“scientist â€™” a dying breed?. <i>Nature Reviews Urology</i> , 2016, 13, 698-699.	1.9	9
64	Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 248-253.	0.7	3
65	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2016, 196, 321-326.	0.2	14
66	Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 1653-1663.	0.4	41
67	Mouse Spermatogenesis Requires Classical and Nonclassical Testosterone Signaling ¹ . <i>Biology of Reproduction</i> , 2016, 94, 11.	1.2	74
68	The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. <i>Oncotarget</i> , 2016, 7, 64921-64931.	0.8	35
69	EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. <i>Oncotarget</i> , 2015, 6, 3811-3824.	0.8	63
70	Progesterone receptor modulates ERÎ± action in breast cancer. <i>Nature</i> , 2015, 523, 313-317.	18.7	504
71	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2015, 85, 876-882.	0.5	27
72	Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 487-499.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Minireview: Deciphering the Cellular Functions of PELP1. <i>Molecular Endocrinology</i> , 2015, 29, 1222-1229.	3.7	18
74	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. <i>Urology</i> , 2015, 86, 1146-1152.	0.5	25
75	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	0.6	11
76	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. <i>Nucleic Acids Research</i> , 2015, 43, 5880-5897.	6.5	136
77	KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. <i>Chemistry and Biology</i> , 2015, 22, 1185-1196.	6.2	66
78	Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. <i>Human Pathology</i> , 2015, 46, 1829-1835.	1.1	22
79	Expression of androgen receptor splice variants in clinical breast cancers. <i>Oncotarget</i> , 2015, 6, 44728-44744.	0.8	77
80	Tailoring Peptidomimetics for Targeting Protein-Protein Interactions. <i>Molecular Cancer Research</i> , 2014, 12, 967-978.	1.5	41
81	The social network of PELP1 and its implications in breast and prostate cancers. <i>Endocrine-Related Cancer</i> , 2014, 21, T79-T86.	1.6	17
82	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4251-4256.	3.3	110
83	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.2	29
84	Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2014, 191, 1485-1490.	0.2	19
85	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	0.8	31
86	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , 2013, 10, 483-487.	1.9	111
87	Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. <i>Nature Communications</i> , 2013, 4, 1923.	5.8	125
88	Emerging drugs for prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 533-550.	1.0	10
89	Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. <i>Translational Andrology and Urology</i> , 2013, 2, 187-96.	0.6	70
90	Significance of PELP1 in ER-Negative Breast Cancer Metastasis. <i>Molecular Cancer Research</i> , 2012, 10, 25-33.	1.5	38

#	ARTICLE	IF	CITATIONS
91	Central Role for PELP1 in Nonandrogenic Activation of the Androgen Receptor in Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 550-561.	3.7	45
92	Dual Roles of PARP-1 Promote Cancer Growth and Progression. <i>Cancer Discovery</i> , 2012, 2, 1134-1149.	7.7	354
93	Effect of Testicular Germ Cell Tumor Therapy on Renal Function. <i>Urology</i> , 2012, 80, 641-648.	0.5	29
94	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by <i>Ex Vivo</i> Culture of Human Prostate Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 3562-3570.	3.2	92
95	Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. <i>Journal of Clinical Investigation</i> , 2012, 122, 2469-2481.	3.9	89
96	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4678-TPS4678.	0.8	0
97	Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2011, 117, 276-282.	2.0	129
98	Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line. <i>Prostate</i> , 2011, 71, 626-636.	1.2	7
99	Demonstration of Cancer Cell Migration Using a Novel Microfluidic Device. <i>Journal of Nanotechnology in Engineering and Medicine</i> , 2010, 1, .	0.8	5
100	Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. <i>European Urology</i> , 2009, 55, 164-176.	0.9	1,145
101	The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. <i>Cancer</i> , 2008, 113, 2681-2686.	2.0	21
102	Renal Function Outcomes in Patients Treated for Renal Masses Smaller Than 4 cm by Ablative and Extirpative Techniques. <i>Journal of Urology</i> , 2008, 179, 75-80.	0.2	186
103	Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer. <i>Journal of Urology</i> , 2008, 179, 2146-2151.	0.2	107
104	Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 1283-1286.	0.2	146
105	Radical Cystectomy and Lymphadenectomy for Invasive Bladder Cancer: Towards the Evolution of an Optimal Surgical Standard. <i>Seminars in Oncology</i> , 2007, 34, 110-121.	0.8	19
106	Association Between Urinary Cytology and Pathology for Nontransitional Cell Malignancies of the Urinary Tract. <i>Journal of Urology</i> , 2006, 175, 2038-2041.	0.2	10
107	Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2006, 7, 735-740.	5.1	1,456
108	Natural History of Positive Urinary Cytology After Radical Cystectomy. <i>Journal of Urology</i> , 2006, 176, 2000-2005.	0.2	25

#	ARTICLE	IF	CITATIONS
109	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. <i>Cancer</i> , 2006, 107, 2167-2172.	2.0	69
110	Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3095-3100.	0.8	67
111	Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. <i>Modern Pathology</i> , 0, , .	2.9	3